Eton Pharmaceuticals - ETON Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETON shares.
View ETON analyst ratings or view top-rated stocks.

1 brokers have issued twelve-month target prices for Eton Pharmaceuticals' stock. Their ETON share price forecasts range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 231.1% from the stock's current price.
View analysts price targets for ETON or view top-rated stocks among Wall Street analysts.

Eton Pharmaceuticals' stock was trading at $4.29 on January 1st, 2022. Since then, ETON stock has decreased by 29.6% and is now trading at $3.02.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our ETON earnings forecast.

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its quarterly earnings results on Thursday, November, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03. The business earned $3.22 million during the quarter, compared to analysts' expectations of $3 million. Eton Pharmaceuticals had a negative net margin of 47.19% and a negative trailing twelve-month return on equity of 64.18%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA).

(ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation served as the underwriter for the IPO.

Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON."

Eton Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.66%), Westside Investment Management Inc. (1.87%), Paradigm Capital Management Inc. NY (1.19%), State Street Corp (0.28%), Citadel Advisors LLC (0.08%) and Virtu Financial LLC (0.07%). Insiders that own company stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen.
View institutional ownership trends.

Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ETON stock can currently be purchased for approximately $3.02.

Eton Pharmaceuticals (NASDAQ:ETON) has a market capitalization of $76.41 million and generates $21.83 million in revenue each year. The company earns $-1,960,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The official website for the company is www.etonpharma.com. The company can be reached via phone at (847) 787-7361 or via email at investorrelations@etonpharma.com.